Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA
Authors' conclusion
Management of cSLE and aSLE includes the same medication classes; differences include more intensive use of therapy in cSLE
Study context
- Population
- US patients (MarketScan) with confirmed SLE diagnosis 2010–2019 and ≥12 months continuous enrolment pre- and post-index; stratified as new or existing SLE
- Participants
- 1,275 vs 66,326
- Exposure
- Childhood-onset SLE vs adult-onset SLE
- cSLEn = 1,275
- aSLEn = 66,326reference
- Outcome
- Treatment regimens (all patients); adherence (PDC) and discontinuation of therapies initiated within 90 days of diagnosis (new patients)
- Follow-up
- Post-index period
Methodological detailsclaims database, univariate comparisons (Wilcoxon rank-sum and χ2 or Fisher's exact tests)
- Claims database
- Univariate comparisons (Wilcoxon rank-sum and χ2 or Fisher's exact tests)
Main finding
As reported in the abstract
Treatment regimens, adherence and discontinuation
- cSLE
- median oral GC dose (prednisone equivalent), new patients 22.1 vs 14.0 mg/day; P < 0.05
- cSLE
- median oral GC dose (prednisone equivalent), existing patients 14.4 vs 12.3 mg/day; P < 0.05
- cSLE
- MMF use, new patients 26.2% vs 5.8%; P < 0.0001
- cSLE
- MMF use, existing patients 37.6% vs 11.0%; P < 0.0001
- cSLE
- median proportion of days covered (PDC), antimalarials 0.9 vs 0.8; P < 0.0001
- cSLE
- median PDC, oral GC 0.6 vs 0.3; P < 0.0001
- cSLE
- discontinuation, antimalarials 25.0% vs 33.1%; P < 0.0001
- cSLE
- discontinuation, oral GC 56.6% vs 71.2%; P < 0.0001
Observational data: associations, not effects.
Original publication
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. Published 10 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →